platoseedplatoseed
Gen-AI Designed Enzymes for Pharmaceutical Innovation
Pando is an AI-driven synthetic biology company revolutionizing enzyme engineering for the pharmaceutical industry. Our ultra-high-throughput screening platform screens 1000-fold more enzymes 75% faster and 80% cheaper than traditional methods. This empowers our generative AI to efficiently optimize enzymes across multiple properties, delivering high-performing, tailored enzymes that reduce costs and enhance efficiency.
Pando Bioscience is an AI-driven synthetic biology company focused on engineering industrial-grade enzymes for pharmaceutical manufacturing and diagnostics. It emphasizes an ultra-high-throughput screening platform that accelerates and reduces costs in enzyme optimization for manufacturability, stability, and activity. The company positions itself as providing AI-guided iterative enzyme improvement and tailored enzyme solutions for pharma applications.
Pando leverages an AI-powered internal screening platform to engineer enzymes. The platform enables ultra-high-throughput screening that purportedly analyzes 1000-fold more enzymes, delivering faster and cheaper optimization than traditional methods. Products include proprietary engineered enzymes for molecular biology applications, plus tailored enzyme solutions offered as a service. The approach combines AI models with iterative enzyme improvement to optimize multiple properties (e.g., manufacturability, stability, activity) to produce high-performing, industrial-grade enzymes for pharma manufacturing and diagnostics.
Who it’s for: Pharmaceutical manufacturers and diagnostic developers seeking optimized industrial-grade enzymes and cost-reducing enzyme workflows.
Founding activity evidenced by product/services offering, internal AI/screening platform, and customer-focused promises; appears to be in growth/market-entry phase with ongoing outreach (contact options) and 2025 copyright.
Will Cao is the co-founder and CEO of Pando Bioscience. During her Ph.D., Will changed her major from engineering machines to engineering bacteria (yes, making genetic modifications to bacteria, so they can produce things that they can't before). She has published first-author papers in Cell and Nature Biotechnology. In her spare time, she is a personal trainer and a kayak and scuba diving enthusiast.
Unlocking the full potential of enzymes to drive down costs and boost productivity in pharma
Pando presents an AI-driven synthetic biology platform for pharma enzyme engineering, combining AI-designed mutations with an ultra-high-throughput one-pot screening to design and test enzymes across multiple properties. It aims to reduce design-build-test-learn cycles to one month, helping pharma companies improve existing enzymes, discover new ones, and cut costs while boosting productivity.
From the original launch (Feb 2023) — may be outdated.
Enzyme design models.
AI-Native FDA Regulatory Services
